Big Pharma delivers another life-saving medical advance, and another demonstration of the folly of price controls.

Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

What kind of uptake can Gilead expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) injection ...

The drug is groundbreaking, potentially eliminating the need for a long-sought-after HIV vaccine. In her own words: Anne ...

The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who ...

Gilead Sciences (NasdaqGS:GILD) recently entered an exclusive agreement with Kymera Therapeutics to advance a molecular glue ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

Gilead’s HIV treatment trials involving GS-1720 and GS-4182 have been put on clinical hold by the Food and Drug Administration.

Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an ...

The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.